While analyzing the prescriptions, the academics found that most frequently prescribed anticholinergic drugs were bladder antimuscarinic drugs
, antidepressants, drugs for treating vomiting, motion sickness and drugs to treat vertigo.
Despite their established clinical efficacy in the medical treatment of OAB, the side effects, tolerability issues, and low persistence rates associated with antimuscarinic drugs
have contributed to the development of alternative, non-muscarinic targets for OAB pharmacotherapy.
It has been proven that all classes of antiparkinsonian drugs (dopamine receptor agonists, N-methyl D-aspartate (NMDA) receptor antagonists, levodopa, monoamine oxidase B inhibitors of catechol-O-methyltransferase and antimuscarinic drugs
) may induce psychotic symptoms .
Anticholinergic, antimuscarinic drugs
relax the bladder muscle and reduce bladder spasms (oxybutynin).
Moreover, OXY-TDS showed reductions similar to other antimuscarinic drugs
. Findings from a review of randomized controlled trials with antimuscarinic drugs
for OAB conducted by Novara et al.
, alone or in combination with intermittent self-catheterization, are currently the mainstay of conservative treatment, and several other medications may help in specific disease conditions.
Patients with a history of bladder cancer or colorectal cancer and patients on treatment on antimuscarinic drugs
, beta 3 adrenoceptor agonists, or laxatives were not included because these diseases or drugs may influence urination or bowel activity.
Anticholinergic or antimuscarinic drugs
work by blocking the effects of a chemical called acetylcholine, which the nervous system uses to activate the sweat glands.
26, 2015 in JAMA Internal Medicine, people who took high doses of tricyclic antidepressants such as doxepin (Sinequan), diphenhydramine (Benadryl), older antihistamines such as chlorpheniramine (Chlor-Trimeton), or antimuscarinic drugs
for bladder control, such as oxybutynin (Ditropan) for longer than three years were significantly more likely to develop dementia.
such as oxybutynin are used as first-line pharmacotherapy with a proven clinical benefit.
The major difference between these antimuscarinic drugs
is the duration of action.
Second-line treatments include oral antimuscarinic drugs
or mirabegron, preferably in an extended-release formulation if available to reduce the likelihood of dry mouth from immediate-release formulations.